This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Investigating the data from the Phase 3 ZENITH clinical trial of Winrevair (Sotatercept-csrk) in patients with PAH.

Ticker(s): MRK

Who's the expert?

Expert 1: Dr. Stephen Lee

  1. I probably have at least 100-150 patients with bronchiectasis that I manage, maybe more, not any less.
  2. I am familiar with the trial results published in the NEJM.

Interview Goal
to discuss the current treatment landscape and the potential of Winrevair (Sotatercept-csrk), an activin signaling inhibitor being developed by Merck for the treatment of PAH.

Do you want answers to these questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.